NSC 12 is an orally bioavailable pan-FGF inhibitor that traps FGF ligands, blocking FGFR1 signaling and disrupting tumor-promoting ternary complex formation without affecting heparin binding. It demonstrates antitumor activity by inhibiting cancer cell proliferation, angiogenesis, and metastasis in both cellular assays and animal models.